MarsBars A recent article highlighted keys to success for Amazon (AMZN) CEO, Andy Jassy, in which he attributed the following points to an 'embarrassing' amount of success. Specifically, he remarked on the following points in which a career professional should be able to confidently answer 'yes' to: Do you work hard? Are you more can-do than naysaying? Do you do what you said you were going to do? Can you work in a team? These are all admirable traits and while they don’t translate in the same to succ ...

This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come.Searching for investments that can outperform the benchmark S&P 500 index often gets wickedly complicated. If you're new to the investing process, you'll be glad to learn that building a portfolio that can outperform the broad market isn't as difficult as it seems.Filling your portfolio with top dividend-paying stocks doesn't guarantee great returns, but you'd have to be unlucky to underpe ...

Trevor Williams The first-quarter earnings season is largely in the books. S&P 500 operating EPS growth was solid at 6.4%. Critics contend that if you back out the very impressive profits from the Magnificent 7 stocks, then the market’s earnings growth rate is less sublime. I counter that argument with the reality that, if you also remove the roughly $13 billion of total acquisition and transaction costs related to several deals closed in the first quarter by Bristol-Myers Squibb Company (NYSE:BMY), th ...

Bristol Myers Squibb (BMY) announced that the European Commission (EC) has approved its blockbuster immuno-oncology drug, Opdivo (nivolumab), in combination with a chemotherapy combination, cisplatin and gemcitabine, as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma (UC).Following the approval in Europe, the Opdivo combination became the first concurrent immunotherapy-chemotherapy approved for treating adult patients with unresectable or metastatic UC in a fir ...

Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service.  We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...

In this articleAZN-GBBMYLLYNVSNOV.N-CHSkynesher | E+ | Getty ImagesBig pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a "massive opportunity."It's called targeted radiopharmaceuticals. The therapy essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.RBC Capital Markets sees a $25 billion market opportunity for the space."We believe TRT development is still in its early stages, and next- ...

This top pharma stock has fallen too far.Dividend stocks are an important anchor for well-balanced portfolios. Regular cash distributions can buffer a portfolio against market volatility and provide a steady income across business cycles.Still, picking dividend stocks is no easy task. Companies operating in high-tech areas like healthcare often face unique competitive pressures that can diminish free cash flows, lowering their ability to reward shareholders via ever-larger dividend checks. Bristol Myers Squ ...

Bristol Myers Squibb (BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024.The subcutaneous formulation of Opdivo is co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20). The BLA seeks approval of the same across all previously approved adult, solid tumor indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or i ...

Core Insights - NeoPhore Limited has secured additional funding from Bristol Myers Squibb to advance its research on the DNA mismatch repair (MMR) pathway in cancer and to progress its lead program towards candidate selection by 2025 [1][2]. Company Overview - NeoPhore is focused on developing small molecule drugs that target novel proteins within the MMR pathway, aiming to create next-generation immuno-oncology therapeutics to enhance clinical outcomes for cancer patients [2][3]. - The company was established as a spin-out from the University of Turin and PhoreMost Ltd, supported by the CRT Pioneer Fund [3]. Investment Details - The Series B extension round was oversubscribed, indicating strong investor interest and confidence in NeoPhore's approach [1][2]. - The funding will facilitate the completion of necessary pre-clinical studies for NeoPhore's lead PMS2 program [2]. Strategic Importance - The collaboration with Bristol Myers Squibb, a leader in the immuno-oncology field, is expected to bolster NeoPhore's position and accelerate its research efforts [2][4]. - NeoPhore's MMR inhibitors are designed to induce neoantigen expression, which enhances the immunogenicity of solid tumors, making them more responsive to immunotherapy [2].

Key PointsPerspective Therapeutics' major shareholder doubled down on the position, validating the business and pipeline. Liberty Live Group's SiriusXM stock is bought by Warren Buffett and Berkshire Hathaway. NB Bancorp is an aged institution that recently IPOd with great success; it is still undervalued. The threat of fines and imprisonment, up to twenty years for the worst offenders, makes insider trading a different game than what it was. Today, insiders must reveal their trading within days of executio ...